<DOC>
	<DOCNO>NCT03006445</DOCNO>
	<brief_summary>The purpose study confirmatory investigation safety efficacy FYU-981 administer orally hyperuricemic patient without gout 34 58 week method multicenter , open label ascend dose regimen .</brief_summary>
	<brief_title>Study FYU-981 Hyperuricemia With Without Gout</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<criteria>Hyperuricemic gout patient Serum urate level : &gt; = 7.0mg/dL patient history gout , &gt; = 8.0mg/dL patient hypertension , diabetes metabolic syndrome , &gt; = 9.0mg/dL Gouty arthritis within two week start study treatment Secondary hyperuricemia HbA1c : &gt; = 8.4 % Uric acidoverproduction type classification hyperuricemia History , clinically significant cardiac , hematologic hepatic disease Kidney calculi clinically significant urinary calculus eGFR : &lt; 30mL/min/1.73m^2 Systolic blood pressure : &gt; = 180 mmHg Diastolic blood pressure : &gt; = 110 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>